Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced that Walter C. Ogier, President and Chief Executive Officer of Acetylon, participated in the Wells Fargo Celgene Partnership Forum. Mr. Ogier discussed Acetylon’s pipeline of selective HDAC inhibitors this morning on the panel entitled, “Express Yourself: Using Epigenetics to Transform Cancer Treatment.”
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
